Print | Email Page

Celgene asserts its POMALYST® patents against multiple generic companies under Hatch-Waxman Act

Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against multiple pharmaceutical companies including Teva Pharmaceuticals USA, Inc.; Apotex, Inc.; Hetero Labs Limited; Aurobindo Pharma Ltd.; Mylan Pharmaceuticals Inc.; Breckenridge Pharmaceutical, Inc.; and Natco Pharma Limited in several Hatch-Waxman litigation matters involving their proposed generic versions of POMALYST®, which is prescribed for treating multiple myeloma.

Celgene Corporation v. Hetero Labs Limited, et al., Nos. 2-17-cv-03387, 2-18-cv-14111 (D.N.J.); Celgene Corporation v. Teva Pharmaceuticals USA Inc., et al., No. 2-18-cv-14366 (D.N.J.); Celgene Corporation v. Breckenridge Pharmaceutical, Inc., et al., No. 2-18-cv-14715 (D.N.J.); Celgene Corporation v. Mylan Pharmaceuticals Inc. et al., No. 2-18-cv-16035 (D.N.J.); Celgene Corporation v. Apotex, Inc., No. 2-18-cv-16395 (D.N.J.); Celgene Corporation v. Aurobindo Pharma Limited, et al., No. 2-19-cv-00143 (D.N.J.)

For additional information about this matter, please contact: Anthony M. Insogna, Cary Miller Ph.D., Matthew J. Hertko

Client(s): Celgene Corporation
Office(s): San Diego, Chicago